Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Orsi

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
European Journal of Cancer (Oxford, England : 1990)|July 19, 2024
Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patientsGiulia Orsi, Catia Carconi, Paola Ghiorzo, et al.
Lancet (London, England)|November 23, 2025
Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trialMichele Reni, Marina Macchini, Giulia Orsi, et al.
Targeted Oncology|October 28, 2020
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular CarcinomaGiulia Orsi, Francesco Tovoli, Vincenzo Dadduzio, et al.
Targeted Oncology|October 12, 2020
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular CarcinomaGiulia Orsi, Francesco Tovoli, Vincenzo Dadduzio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2020
Association of <i>NOS3</i> and <i>ANGPT2</i> Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE StudyAndrea Casadei-Gardini, Giorgia Marisi, Vincenzo Dadduzio, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|April 2, 2025
Diagnostic delay at diagnosis and time-to-treatment influence overall survival of pancreatic cancer patientsRuggero Ponz de Leon Pisani, Livia Archibugi, Pilar Lazzano, et al.
Journal of Gastrointestinal Cancer|February 5, 2021
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS IndexGiulia Rovesti, Francesco Leone, Giovanni Brandi, et al.
Cancer Medicine|January 25, 2025
Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic VariantsMichele Milella, Giulia Orsi, Mariacristina di Marco, et al.
British Journal of Cancer|December 9, 2022
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv)Giulia Orsi, Alessandro Cavaliere, Giampaolo Tortora, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 14, 2025
Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinomaDaniel Oyon, Amaya Lopez-Pascual, Borja Castello-Uribe, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
European Journal of Cancer (Oxford, England : 1990)|July 19, 2024
Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patientsGiulia Orsi, Catia Carconi, Paola Ghiorzo, et al.
Lancet (London, England)|November 23, 2025
Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trialMichele Reni, Marina Macchini, Giulia Orsi, et al.
Targeted Oncology|October 28, 2020
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular CarcinomaGiulia Orsi, Francesco Tovoli, Vincenzo Dadduzio, et al.
Targeted Oncology|October 12, 2020
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular CarcinomaGiulia Orsi, Francesco Tovoli, Vincenzo Dadduzio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2020
Association of <i>NOS3</i> and <i>ANGPT2</i> Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE StudyAndrea Casadei-Gardini, Giorgia Marisi, Vincenzo Dadduzio, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|April 2, 2025
Diagnostic delay at diagnosis and time-to-treatment influence overall survival of pancreatic cancer patientsRuggero Ponz de Leon Pisani, Livia Archibugi, Pilar Lazzano, et al.
Journal of Gastrointestinal Cancer|February 5, 2021
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS IndexGiulia Rovesti, Francesco Leone, Giovanni Brandi, et al.
Cancer Medicine|January 25, 2025
Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic VariantsMichele Milella, Giulia Orsi, Mariacristina di Marco, et al.
British Journal of Cancer|December 9, 2022
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv)Giulia Orsi, Alessandro Cavaliere, Giampaolo Tortora, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 14, 2025
Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinomaDaniel Oyon, Amaya Lopez-Pascual, Borja Castello-Uribe, et al.
Pageof 6